Descovy

HIV-1 Treatment

Descovy is used in combination with other antiretroviral medications to treat human immunodeficiency virus type 1 (HIV-1) infection. It is approved for use in adults and children who meet specific weight requirements. While the medication helps control the amount of HIV in the body and supports the immune system, it is not a cure for HIV or AIDS.

HIV-1 Prevention (PrEP)

This medication is also used for pre-exposure prophylaxis (PrEP) to lower the risk of getting HIV-1 through sex. It is intended for adults and adolescents weighing at least 35 kg (77 lbs) who are at high risk of infection. For prevention to be effective, the medication must be taken consistently every day.

Important Limitations and Requirements

• Vaginal Sex: Descovy is not indicated for HIV-1 prevention in individuals at risk through receptive vaginal sex. Its effectiveness for prevention has not been evaluated in this specific population.
• HIV Testing: Before starting the medication for PrEP, a person must have a confirmed negative HIV-1 test. Taking the drug for prevention while already having an HIV-1 infection can cause the virus to become resistant to treatment, making it much harder to manage.
• Comprehensive Prevention: When used for PrEP, this medication should be part of a complete prevention strategy that includes regular HIV testing and safer sex practices.

Mechanism of Action

Descovy is a combination of two active ingredients: emtricitabine and tenofovir alafenamide. Both medications belong to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs).

To multiply and spread throughout the body, HIV must convert its genetic material (RNA) into DNA. The virus uses a protein called reverse transcriptase to complete this process. The ingredients in Descovy act as decoys that mimic the natural building blocks the virus needs. When the virus attempts to use these decoys to build its DNA, the process is interrupted, and the virus is unable to create functional copies of itself.

How It Functions in the Body

The medication serves different roles depending on whether it is used for treatment or prevention:

• Treatment of HIV: In individuals already living with HIV, Descovy is used alongside other antiretroviral medications. By stopping the virus from replicating, it reduces the viral load (the amount of HIV in the blood). This allows the immune system, specifically CD4 cells, to recover and better protect the body from other infections.
• Prevention of HIV (PrEP): When used as pre-exposure prophylaxis (PrEP), the medication is taken to maintain a consistent level of the drug in the bloodstream and tissues. If a person is exposed to HIV, the drug is already present to block the virus from replicating, which prevents it from establishing a permanent infection in the body.

By interfering with the life cycle of the virus, the medication helps manage the progression of the infection or provides a barrier against new infections.

Common Side Effects

Many people taking Descovy experience mild side effects. These may include:

• Nausea
• Headache
• Diarrhea
• Fatigue
• Stomach pain

Serious Side Effects

Some side effects can be severe and require immediate medical attention. Contact a healthcare provider right away if you notice symptoms of the following conditions:

• Lactic acidosis: This is a serious medical emergency caused by a buildup of lactic acid in the blood. Symptoms include unusual tiredness, muscle pain, shortness of breath, stomach pain with vomiting, and feeling cold or dizzy.
• Liver problems: Signs of liver damage include yellowing of the skin or the whites of the eyes, dark urine, light-colored stools, and loss of appetite.
• Kidney impairment: Descovy can cause new or worsening kidney problems. Doctors typically monitor kidney function through blood and urine tests during treatment.
• Bone loss: Some people may experience a decrease in bone mineral density, which can lead to bone pain or an increased risk of fractures.
• Immune system changes: Also known as immune reconstitution syndrome, this occurs when the immune system becomes more active and reacts to hidden infections.

Boxed Warnings

Hepatitis B Exacerbation: Individuals with both HIV-1 and hepatitis B virus (HBV) may experience a severe worsening of their hepatitis infection if they stop taking Descovy. Liver function should be monitored closely for several months after discontinuing the medication.

HIV-1 Resistance: When used for HIV-1 pre-exposure prophylaxis (PrEP), Descovy must only be prescribed to individuals who are confirmed to be HIV-negative immediately before starting and at least every three months during use. Taking Descovy while having an undiagnosed HIV infection can lead to the virus developing resistance to the medication, making future treatment more difficult.

Kidney and Bone Health

New or worsening kidney impairment, including cases of kidney failure, has been reported with the use of medications containing tenofovir. Healthcare providers usually perform blood and urine tests to check kidney function before and during treatment.

A decrease in bone mineral density can occur while taking this medication. This may increase the risk of bone fractures in some individuals.

Other Serious Risks

• Lactic Acidosis and Liver Problems: A dangerous buildup of lactic acid in the blood (lactic acidosis) and severe liver enlargement (hepatomegaly) have occurred in people taking similar medications. These conditions can be life-threatening.
• Immune Reconstitution Syndrome: In patients with HIV, the immune system may become more active and begin to fight previously hidden infections, which can lead to new symptoms shortly after starting treatment.

Pregnancy

There is limited research on the use of Descovy during pregnancy. If you are pregnant or planning to become pregnant, talk to your healthcare provider about the potential risks and benefits. For those treating HIV, maintaining an undetectable viral load is essential for the health of the parent and to prevent transmission of the virus to the baby.

It is important to note that Descovy is not approved for HIV prevention (PrEP) in people assigned female at birth who are at risk of HIV through vaginal sex, as its effectiveness has not been studied in this population.

A pregnancy registry exists to monitor outcomes for people who take antiretroviral medications while pregnant. Healthcare providers use this registry to track the safety of the medication for both the parent and the child.

Breastfeeding

Health authorities generally recommend that people with HIV do not breastfeed to prevent the transmission of HIV to the baby through breast milk. Furthermore, the active ingredients in Descovy, emtricitabine and tenofovir, pass into breast milk. The potential effects of these medications on a nursing infant are not fully known.

Available Forms

Descovy is supplied as a film-coated tablet for oral administration. It is a fixed-dose combination medication, meaning each tablet contains two different active ingredients.

• Oral Tablet: These tablets are swallowed whole and are available in different shapes and colors to identify the specific formulation.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) first approved Descovy in 2016. It is currently approved for two primary uses:

• HIV-1 Treatment: Used in combination with other antiretroviral agents to treat HIV-1 infection in adults and pediatric patients weighing at least 35 kg. It is also approved for certain pediatric patients weighing at least 14 kg to less than 35 kg in specific treatment combinations.
• HIV-1 Pre-Exposure Prophylaxis (PrEP): Used to reduce the risk of sexually acquired HIV-1 infection in at-risk adults and adolescents weighing at least 35 kg. However, it is not indicated for individuals at risk through receptive vaginal sex because its effectiveness in this population has not been evaluated.

Boxed Warnings

Descovy carries a boxed warning, the FDA’s most serious type of warning, for the following risks:

Post-Treatment Acute Exacerbation of Hepatitis B

Patients with both HIV-1 and hepatitis B virus (HBV) infection may experience severe, acute worsening of hepatitis B after they stop taking Descovy. Healthcare providers typically monitor liver function closely for several months in patients who discontinue the medication and have a history of HBV.

Risk of Drug Resistance with PrEP Use

Descovy for PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately before starting the medication and at least every three months while taking it. Using the drug for PrEP while having an undiagnosed HIV-1 infection can lead to the development of drug-resistant HIV-1 strains.

Generic Availability

There is currently no FDA-approved generic version of Descovy available in the United States. The medication remains under patent protection and regulatory exclusivity, which prevents generic manufacturers from marketing the drug at this time.

Insurance and Medicare Coverage

Most private insurance plans, Medicare Part D, and Medicaid cover Descovy for both HIV treatment and PrEP (pre-exposure prophylaxis). However, the specific copay or coinsurance amount depends on the individual plan's formulary. Some insurers may require prior authorization or a medical necessity form from a healthcare provider before they will cover the medication, especially if generic alternatives are available for the same indication.

Financial Assistance Programs

The manufacturer offers several programs to help reduce the cost of Descovy for eligible patients:

• Copay Coupons: For individuals with commercial or private insurance, manufacturer copay cards may reduce out-of-pocket costs to as little as zero dollars per month, up to a specific annual limit.
• Patient Assistance Programs: Programs such as Gilead Advancing Access provide the medication at no cost to individuals who are uninsured or underinsured and meet specific income and residency requirements.

Generic Availability

There is currently no generic version of Descovy available in the United States. The medication is protected by patents, which prevents other companies from producing lower-cost generic equivalents at this time. This lack of competition contributes to the higher retail price of the drug compared to older HIV medications that have generic versions.

PrEP Coverage Requirements

Under the Affordable Care Act, many private health insurance plans are required to cover HIV prevention services, including PrEP, without cost-sharing. While this often applies to generic medications, some plans may also cover Descovy without a copay if a healthcare provider determines it is medically necessary for the patient. Patients should check with their insurance provider to understand how Descovy is classified under their specific prevention benefits.